FDA approves Johnson & Johnson’s nasal spray for depression

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.
Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.
Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The FDA just approved this ketamine-derived nasal spray for depression treatment
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone treatment for adults with major depressive disorder who have not responded to at least two other antidepressants.
FDA allows standalone use of nasal spray antidepressant Spravato
The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression.
Nose spray to treat depression? FDA approves first-of-its-kind medicine
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.
Research indicates recreational ketamine use is on the rise
Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...
Too Old to Operate3d
Safety and Feasibility of Intranasal Ketamine in Depression Treatment
The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant ...
US Weekly on MSN7d
What Celebrities and Doctors Have Said About Ketamine Use: Chrissy Teigen, Matthew Perry, More
Celebrities like Chrissy Teigen and Matthew Perry have been open about using ketamine for their mental health – here's what ...
NJBIZ1d
J&J’s ketamine-based drug approved as standalone treatment
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
Medscape2d
Ketamine-Induced Uropathy: What Urologists Need to Know
A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...
kffhealthnews1d
Study: Recreational Ketamine Outpaces Therapeutic Use For Depression
Also in the news, "renal denervation" shows promise as a treatment for high blood pressure; an estimated 17 million U.S. adults struggle with long-covid with no new treatments in sight; inequality ...
J&J wins label expansion for depression therapy Spravato
Johnson & Johnson (NYSE:JNJ) announced Tuesday that the U.S. FDA approved a supplemental New Drug Application for its ...
Psychology Today5d
New Strategies for Treatment-Resistant Depression
Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...